Drugs / ASC10
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05596045 | Nov 2022 → Mar 2023 | COVID-19 | Ascletis Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05523141 | Oct → Nov 2022 | COVID-19 | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-12 | Ascletis Pharmaceuticals Co., Ltd. | Results Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19 ascletis.com ↗
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces positive topline results from its Phase I multiple ascending dose (MAD) study ( NCT05523141 ) in healthy subjects for oral RNA-dependent RNA polymerase (RdRp) inhibitor ASC10 for COVID-19 treatment. |
| 2022-11-16 | Ascletis Pharmaceuticals Co., Ltd. | Regulatory Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA ascletis.com ↗
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of ASC10 for monkeypox indication. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-19 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives ascletis.com ↗ |
| 2022-12-12 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19 ascletis.com ↗ |
| 2022-11-16 | Ascletis Pharmaceuticals Co., Ltd. | Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA ascletis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC10 | “In this study, ASC10, a novel antiviral prodrug, was studied in a phase 1 trial in healthy Chinese participants.” PMID 38988285 ↗ Jul 2024 |
| Route | Oral | “Two single oral doses of ASC10 will be administered to participants” NCT05523141 ↗ |